Document is current
Any future updates will be listed below
-
Authors
Glazer, Andrew M.
Tabet, Daniel R.
Parikh, Victoria N.
Kroncke, Brett M.
Cote, Atina G.
Yamamoto, Yuta https://orcid.org/0000-0001-6129-9745
Wang, Qianru https://orcid.org/0000-0002-7219-7522
Muhammad, Ayesha
Lancaster, Megan C. https://orcid.org/0000-0002-2697-3762
O’Neill, Matthew J.
Weile, Jochen
Yang, Tao
Macrae, Calum A. https://orcid.org/0000-0001-5181-2664
Ashley, Euan A. https://orcid.org/0000-0001-9418-9577
Roth, Frederick P.
Roden, Dan M. https://orcid.org/0000-0002-6302-0389
- License Information
-
More Information
Article History
Accepted: 4 August 2025
First Online: 1 September 2025
Competing interests
: A.M.G. is a consultant for BioMarin. V.N.P. is a consultant and Scientific Advisory Board member for Lexeo Therapeutics, clinical adviser for Constantiam Biosciences, consultant and conducts sponsored research for BioMarin and minor consultant for Nuevocor and Borealis. C.A.M. is founder of Atman Health and Tanaist Bio; adviser for Adrestia, Affinia, Alliance of Genomic Resources, Astellas, BioSymetrics, Dewpoint, Foresite Labs, EOM and Nuevocor; non-executive director of Life MD, TMA Precision Medicine and Tanaist Bio; owns stock from BioSymetrics, Bodyport, Life MD and TMA Precision Medicine; and has provided in-kind collaborative support to Astra Zeneca, Quest Diagnostics and Apple. E.A.A. is a founder of Candela, Deepcell, Parameter Health, Personalis, Saturnus Bio and Svexa; is an adviser for SequenceBio, Foresite Labs, Pacific Biosciences and Versant Ventures; is a non-executive director of AstraZeneca and Svexa; owns stock from Pacific Biosciences and AstraZeneca; and has provided in-kind collaborative support to Cache, Cellsonics, Illumina, Oxford Nanopore and Pacific Biosciences. F.P.R. is an adviser for and shareholder of Constantiam Biosciences. The other authors declare no competing interests.
